Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second line NSCLC
Melanoma combination study reports safety and efficacy
PR Newswire
BERGEN, Norway, Oct. 22, 2018
PR Newswire
BERGEN, Norway, Oct. 22, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey